WordNet

use recreational drugs (同)do drugs
administer a drug to; "They drugged the kidnapped tourist" (同)dose
a substance that is used as a medicine or narcotic
an antibody that can neutralize a specific toxin

PrepTutorEJDIC

『薬』,薬品,薬剤 / 『麻薬』,麻酔剤 / 〈人〉‘に'薬(特に麻酔剤)を与える / 〈飲食物〉‘に'(麻酔薬・毒薬などの)薬を混ぜる
〈C〉抗毒素 / 〈U〉抗毒素血清

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 薬物アレルギー患者へのアプローチ an approach to the patient with drug allergy
2. 抗マラリア剤：概要 antimalarial drugs an overview
3. 成人における薬物中毒への一般的アプローチ general approach to drug poisoning in adults
4. Overview of immunosuppressive and conventional (non-biologic) disease-modifying drugs in the rheumatic diseases
5. 処方剤の誤用：疫学、予防、同定、およびマネージメント prescription drug misuse epidemiology prevention identification and management

English Journal

Special considerations for prophylaxis for and treatment of anthrax in pregnant and postpartum women.

Meaney-Delman D, Zotti ME, Creanga AA, Misegades LK, Wako E, Treadwell TA, Messonnier NE, Jamieson DJ; Workgroup on Anthrax in Pregnant and Postpartum Women.AbstractIn August 2012, the Centers for Disease Control and Prevention, in partnership with the Association of Maternal and Child Health Programs, convened a meeting of national subject matter experts to review key clinical elements of anthrax prevention and treatment for pregnant, postpartum, and lactating (P/PP/L) women. National experts in infectious disease, obstetrics, maternal fetal medicine, neonatology, pediatrics, and pharmacy attended the meeting, as did representatives from professional organizations and national, federal, state, and local agencies. The meeting addressed general principles of prevention and treatment for P/PP/L women, vaccines, antimicrobial prophylaxis and treatment, clinical considerations and critical care issues, antitoxin, delivery concerns, infection control measures, and communication. The purpose of this meeting summary is to provide updated clinical information to health care providers and public health professionals caring for P/PP/L women in the setting of a bioterrorist event involving anthrax.
Emerging infectious diseases.Emerg Infect Dis.2014 Feb;20(2). doi: 10.3201/eid2002.130611.
In August 2012, the Centers for Disease Control and Prevention, in partnership with the Association of Maternal and Child Health Programs, convened a meeting of national subject matter experts to review key clinical elements of anthrax prevention and treatment for pregnant, postpartum, and lactating
PMID 24457117

Centers for disease control and prevention expert panel meetings on prevention and treatment of anthrax in adults.

Hendricks KA, Wright ME, Shadomy SV, Bradley JS, Morrow MG, Pavia AT, Rubinstein E, Holty JE, Messonnier NE, Smith TL, Pesik N, Treadwell TA, Bower WA; Workgroup on Anthrax Clinical Guidelines.Collaborators (50)Anderson M, Artenstein AW, Bartlett J, Beigi R, Bergman N, Booth MG, Donaldson L, Bower WA, Hendricks KA, Hupert N, Jamieson D, Meaney-Delman D, Messonnier NE, Morrow MG, Pesik N, Quinn C, Shadomy SV, Smith TL, Rasmussen S, Treadwell TA, Yu Y, Bradley JS, Cohen D, Nelson L, Corwin HL, Chung S, Drusano GL, Eichacker P, Kurilla M, Wright ME, Friedlander AM, Pitman P, Hart A, Holty JE, Keenan J, Spenkle M, Keitel W, Kelley C, Leissa B, Kovacs GR, Metcalf J, Noel P, Norville K, Pavia AT, Rubinstein E, Stamm LM, Stephens DS, Tessier J, Walsh J, Wendel G.
Emerging infectious diseases.Emerg Infect Dis.2014 Feb;20(2). doi: 10.3201/eid2002.130687.
The Centers for Disease Control and Prevention convened panels of anthrax experts to review and update guidelines for anthrax postexposure prophylaxis and treatment. The panels included civilian and military anthrax experts and clinicians with experience treating anthrax patients. Specialties repres
PMID 24447897

Regulating toxin-antitoxin expression: controlled detonation of intracellular molecular timebombs.

Hayes F1, Kędzierska B2.Author information 1Faculty of Life Sciences and Manchester Institute of Biotechnology, The University of Manchester, 131 Princess Street, Manchester M1 7DN, UK. finbarr.hayes@manchester.ac.uk.2Faculty of Life Sciences and Manchester Institute of Biotechnology, The University of Manchester, 131 Princess Street, Manchester M1 7DN, UK. barbara.kedzierska@biol.ug.edu.pl.AbstractGenes for toxin-antitoxin (TA) complexes are widely disseminated in bacteria, including in pathogenic and antibiotic resistant species. The toxins are liberated from association with the cognate antitoxins by certain physiological triggers to impair vital cellular functions. TAs also are implicated in antibiotic persistence, biofilm formation, and bacteriophage resistance. Among the ever increasing number of TA modules that have been identified, the most numerous are complexes in which both toxin and antitoxin are proteins. Transcriptional autoregulation of the operons encoding these complexes is key to ensuring balanced TA production and to prevent inadvertent toxin release. Control typically is exerted by binding of the antitoxin to regulatory sequences upstream of the operons. The toxin protein commonly works as a transcriptional corepressor that remodels and stabilizes the antitoxin. However, there are notable exceptions to this paradigm. Moreover, it is becoming clear that TA complexes often form one strand in an interconnected web of stress responses suggesting that their transcriptional regulation may prove to be more intricate than currently understood. Furthermore, interference with TA gene transcriptional autoregulation holds considerable promise as a novel antibacterial strategy: artificial release of the toxin factor using designer drugs is a potential approach to induce bacterial suicide from within.
Toxins.Toxins (Basel).2014 Jan 15;6(1):337-58. doi: 10.3390/toxins6010337.
Genes for toxin-antitoxin (TA) complexes are widely disseminated in bacteria, including in pathogenic and antibiotic resistant species. The toxins are liberated from association with the cognate antitoxins by certain physiological triggers to impair vital cellular functions. TAs also are implicated
PMID 24434949